Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations

Gautam Borthakur, MD, Marcos de Lima, MD, Hagop Kantarjian, MD, Lianchun Xiao, MS, Leandro de Padua Silva, MD, Guillermo Garcia-Manero, MD, Sergio Giralt, MD, Farhad Ravandi-Kashani, MD, Sherry Pierce, Richard Champlin, MD

Blood (2008) 112 (11): 3302.

https://doi.org/10.1182/blood.V112.11.3302.3302

Published: 2008

Journal Articles

Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”.

Nitin Jain, MD, Gloria N. Mattiuzzi, MD, Jorge Cortes, MD, Jennifer Cassat, Guillermo Garcia-Manero, MD, Farhad Ravandi-Kashani, MD, Sherry Pierce, Gautam Borthakur, MD, Susan O’Brien, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 2858.

https://doi.org/10.1182/blood.V110.11.2858.2858

Published: 2007

Journal Articles

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Farhad Ravandi-Kashani, MD, Miloslav Beran, MD, PhD, Susan O’Brien, MD

Blood (2007) 110 (11): 2824.

https://doi.org/10.1182/blood.V110.11.2824.2824

Published: 2007

Journal Articles

Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukmia (B-ALL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Jorge Cortes, MD, Stefan Faderl, MD, Farhad Ravandi-Kashani, MD, William Wierda, MD, PhD, Alma Rodriguez, MD, Luis Fayad, MD, Susan O’Brien, MD

Blood (2007) 110 (11): 2825.

https://doi.org/10.1182/blood.V110.11.2825.2825

Published: 2007

Journal Articles

The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL).

Stefan Faderl, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Susan O’Brien, MD, Farhad Ravandi-Kashani, MD, Luis Fayad, MD, Deborah Thomas, MD, Hagop Kantarjian, MD, Mary L. Browning RN, Michael J. Keating MB, BS

Blood (2006) 108 (11): 2827.

https://doi.org/10.1182/blood.V108.11.2827.2827

Published: 2006

Journal Articles

The Clinical Significance of Biphenotypia in Blastic Phase CML.

Constantine S. Tam, MBBS, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, William G. Wierda, MD PhD, Jenny Shan, PhD, Joselle Otero-Palacios, BSc, Ahmed Awais, MD, Farhad Ravandi-Kashani, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 4785.

https://doi.org/10.1182/blood.V108.11.4785.4785

Published: 2006

Journal Articles

Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.

Farhad Ravandi-Kashani, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Miloslav Beran, MD, Sherry Pierce, RN, Charles A. Koller, MD, Jorge Cortes, MD, Stefan Faderl, MD, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 4830.

https://doi.org/10.1182/blood.V108.11.4830.4830

Published: 2006

Journal Articles

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Jeffrey L. Jorgensen, MD, PhD, Stefan Faderl, MD, Jorge Cortes, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Charles Asa Koller, MD, Miloslav Beran, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Dan Jones, MD, PhD, Susan O’Brien, MD

Blood (2006) 108 (11): 1861.

https://doi.org/10.1182/blood.V108.11.1861.1861

Published: 2006

Journal Articles

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.

William G. Wierda, MD, PhD, Susan O’Brien, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Jorge Cortes, MD, Francis Giles, MD, Michael Andreeff, MD, PhD, Charles Asa Koller, MD, Susan Lerner, MS, RHIA, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS

Blood (2006) 108 (11): 31.

https://doi.org/10.1182/blood.V108.11.31.31

Published: 2006

Journal Articles

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Ricardo H. Alvarez, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Farhad Ravandi-Kashani, MD, Srdan Verstovsek, MD, Francis Giles, MD, Susan O’Brien, MD, Charles Asa Koller, MD, Stefan Faderl, MD, Deborah Thomas, MD, John J. Wright, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 1999.

https://doi.org/10.1182/blood.V108.11.1999.1999

Published: 2006

Journal Articles

Combination Therapy with Alemtuzumab and Pentostatin Is Effective and Has Acceptable Toxicity in Patients with T-Lymphoid Neoplasms.

Farhad Ravandi-Kashani, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, Charles Koller, MD, Shirley Odinga, RN, William Wierda, MD, Gautam Borthakur, MD, Dan Jones, MD, Francis Giles, MD, Susan O’Brien, MD, Michael Keating, MD

Blood (2006) 108 (11): 4971.

https://doi.org/10.1182/blood.V108.11.4971.4971

Published: 2006

Journal Articles

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Stefan Faderl, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Gautam Borthakur, MD, Deborah Thomas, MD, Jorge Cortes, MD, Steven M. Kornblau, MD, Zeev Estrov, MD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, DVM, Francis Giles, MD, Xuelin Huang, PhD, Monica Kwari, RN, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 159.

https://doi.org/10.1182/blood.V108.11.159.159

Published: 2006

Journal Articles

Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Leonard Heffner, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Francis Giles, MD, William Wierda, MD, Farhad Ravandi-Kashani, MD, Gavin Choy, PharmD, Gregory I. Berk, MD, Susan O’Brien, MD

Blood (2006) 108 (11): 4539.

https://doi.org/10.1182/blood.V108.11.4539.4539

Published: 2006

Journal Articles

Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study.

Stefan Faderl, MD, William G. Wierda, MD PhD, Susan O’Brien, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Michelle Detry, PhD, Hagop M. Kantarjian, MD, Brandi O’Neal, RN, Michael J. Keating, MB BS

Blood (2006) 108 (11): 2836.

https://doi.org/10.1182/blood.V108.11.2836.2836

Published: 2006

Journal Articles

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Jorge Cortes, MD, Stefan Faderl, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Srdan Verstovsek, MD, Michael Andreeff, MD, PhD, Laurie A. Letvak, MD, Dan Jones, MD, PhD, Richard Champlin, MD, Susan O’Brien, MD

Blood (2006) 108 (11): 284.

https://doi.org/10.1182/blood.V108.11.284.284

Published: 2006

Journal Articles

Clinical Significance of Loss of Chromosome Y (−Y) in Patients with Chronic Myeloid Leukemia (CML): Is It Clonal Evolution?.

Elias Jabbour, MD, Hagop Kantarjian, MD, Farhad Ravandi-Kashani, MD, Guillermo Garcia-Manero, MD, Susan O’Brien, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 2117.

https://doi.org/10.1182/blood.V108.11.2117.2117

Published: 2006

Journal Articles

Combined Therapy with Alemtuzumab and Pentostatin Is Feasible and Effective in T- Lymphoprolifertive Disorders.

Farhad Ravandi-Kashani, MD, Hagop Kantarjian, MD, Srdan Verstovsek, MD, PhD, Alessandra Ferrajoli, MD, William Wierda, MD, PhD, Shirley Odinga, Xueling Huang, Sherry Pierce, Stefan Faderl, MD, Francis Giles, MD, Susan O’Brien, MD, Michael Keating, MD

Blood (2005) 106 (11): 5024.

https://doi.org/10.1182/blood.V106.11.5024.5024

Published: 2005

Journal Articles

Long-Term Follow-Up of Patients with T-Large Granular Lymphocyte Leukemia (T-LGL); Experience in a Single Institution.

Ahmed Aribi, MD, Michael Keating, MD, Susan O’Brien, MD, Alessandra Ferrajoli, MD, Stefan Faderl, MD, Susan Lerner, Charles Koller, MD, William Wierda, MD, PhD, Jorge Cortes, MD, Hagop Kantarjian, MD, Farhad Ravandi-Kashani, MD

Blood (2005) 106 (11): 5026.

https://doi.org/10.1182/blood.V106.11.5026.5026

Published: 2005

Journal Articles

Complete Eradication of Minimal Residual Disease (MRD) in Patients with Hairy Cell Leukemia (HCL) after Cladribine (2CDA) Followed by an Extended Course of Rituximab.

Farhad Ravandi-Kashani, MD, Susan O’Brien, MD, Keating Michael, MD, Dan Jones, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, William Wierda, MD, Shirley Odinga, Sherry Pierce, Charles Koller, MD, Srdan Verstovsek, MD, Jeffrey Jorgensen, MD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 3258.

https://doi.org/10.1182/blood.V106.11.3258.3258

Published: 2005

Journal Articles

Decitabine Low-Dose Schedule (100 mg/m 2 /Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.

Hagop Kantarjian, MD, Susan O’Brien, MD, Francis Giles, MD, Farhad Ravandi-Kashani, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Jan Davis, BS, ADN, Jean-Pierre Issa, MD

Blood (2005) 106 (11): 2522.

https://doi.org/10.1182/blood.V106.11.2522.2522

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations

Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”.

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukmia (B-ALL).

The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL).

The Clinical Significance of Biphenotypia in Blastic Phase CML.

Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.

Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

Combination Therapy with Alemtuzumab and Pentostatin Is Effective and Has Acceptable Toxicity in Patients with T-Lymphoid Neoplasms.

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study.

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Clinical Significance of Loss of Chromosome Y (−Y) in Patients with Chronic Myeloid Leukemia (CML): Is It Clonal Evolution?.

Combined Therapy with Alemtuzumab and Pentostatin Is Feasible and Effective in T- Lymphoprolifertive Disorders.

Long-Term Follow-Up of Patients with T-Large Granular Lymphocyte Leukemia (T-LGL); Experience in a Single Institution.

Complete Eradication of Minimal Residual Disease (MRD) in Patients with Hairy Cell Leukemia (HCL) after Cladribine (2CDA) Followed by an Extended Course of Rituximab.

Decitabine Low-Dose Schedule (100 mg/m 2 /Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only